Tilray is a private company owned by Privateer Holdings, Tilray’s mission is dedicated to advancing the science, efficacy, and safety of medicinal cannabis for patients. Tilray operates one of the largest and most sophisticated federally licensed medical cannabis cultivation facilities in the world, offering a variety of products to patients, pharmacies, and researchers in Canada, Australia, the European Union, and the Americas.
Tilray is relentless in overcoming the stigma of cannabis and wants to prove the benefits of medicinal cannabis to the world. Tilray’s Vice President, Philippe Lucas, explained to the Canadian Press that “they must fight against decades of negative publicity and ‘reefer madness’ over exaggerations in order to change conversations being had about cannabis.”
How is Tilray combating the effects of stigma?
In order to change the negative perceptions on cannabis, Tilray executes in depth cannabis studies on how medicinal cannabis can help those with PTSD and other health related matters. Lucas led a study involving 473 adult medicinal cannabis users and the results displayed that 87% gave up their other medications and decided only to use cannabis. They have also partnered with the government of New South Wales, The University of Sydney, and Chris O’Brien Lifehouse to create a cannabis-based treatment used for patients suffering the side effects of nausea and vomiting from chemotherapy.
Tilray has also teamed up with the Research Institute of the McGill University Health Centre, one of the world’s premier public academic and research institutions, to study the effects of vaporized cannabis on symptoms from chronic obstructive pulmonary disease or COPD. Around 17% of Canadian adults over 40 suffer from COPD, and about 45%-90% of these adults have an advanced case of COPD.
What products are available through Tilray?
Tilray sells fresh cannabis, cannabis oil, and dried cannabis that are available for purchase from their website for registered patients. They have the option of receiving e-mail newsletters that will tell them about new strains that are available including their unique characteristics. The patients usually receive their product within two days of shipment.
Tilray has made a significant change in how it will be marketing its medicinal cannabis products. It used to sell its dry herb under the common strain names (Kush OG, Super Lemon Haze, etc.). However, Tilray has adopted a different system, called Tilray Profiles. This allows for a categorization and packaging system that makes choosing medicinal cannabis products an easier experience.
Canadian cannabis company, Mettrum, was the first to implement this system of labeling cannabis to their business model. Instead of calling a strain “Sour D” they renamed the strain to a more generic name such as “T200”. This essentially creates their own brand which could prove to be helpful and beneficial to them when competing with other similar markets. This new system reflects how the cannabis market is progressing because consumers and patients no longer focus on street names and what sounds “dank”, but focus on the effects of the products from reputable brands.
What’s in the future for Tilray?
Tilray’s future plans are for more studies to include building a larger, multi-site study, and funding a $400,000 clinical trial to study how cannabis can assist with post-traumatic stress disorder.
To learn more about Tilray, check out https://www.tilray.ca/
To read Tamara’s previous article, click here.